Contract research, development and manufacturing organization, AMRI, said in the immediate and near term, it is increasing production of hydroxychloroquine sulfate active pharmaceutical ingredient (API) at its Rensselaer, NY, manufacturing facility to meet the rise in demand resulting from potential effectiveness of the product in treating COVID-19 symptoms. AMRI’s active Type II DMF for hydroxychloroquine sulfate (HCQ) is available to support increased need. The FDA authorized emergency use of HCQ to treat some hospitalized patients with COVID-19.